News

Approximately 4 years of COVID-19…

Here’s why ADHD is a diagnosis of exclusion.

“If we can show that serotonin loss over time is directly involved in the transition from mild cognitive impairment to Alzheimer disease, recently developed antidepressant medications may be an effective way to improve memory deficits and depressive symptoms and, thus, may be a powerful way forward to slow disease progression.”

What positivity emerged from the Oscars?

Over these years psychiatry has made strides in the interfaith relationships that can contribute to unity among religious diversity.

More than a gut feeling? Researchers investigated associations between the gut microbiome and treatment resistance in schizophrenia.

"I can smell the aroma of spring tulips filling the air-spreading peace and good cheer..."

These 5 processes provide a focus for patients with PTSD...

Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.

Using Dune as an indicator of the future of psychiatry…

Check out this case study to learn more about how viral infections might play a role in triggering psychotic disorders.

As we enter the second coming of psychedelics popularity, H. Steven Moffic, MD, looks ahead to their third coming. Will it be similar to that of Dune?

Take a look back at our recent coverage relating to our March content theme.

From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.

New research on transcranial direct current stimulation effectiveness in treating major depressive disorder.

What is new in research on cannabis?

“Advances are made by answering questions. Discoveries are made by questioning answers.”—Bernard Haisch, PhD

Alzheimer disease treatment donanemab will be delayed as the FDA plans to convene a committee meeting to evaluate the phase 3 Trailblazer-Alz 2 trial.

Science fiction or reality? Women’s rights take the center stage in today’s discussion, and in the new movie “Dune: Part Two.”

The screening tool includes multiple tests that assess memory, attention, executive function, reaction times, and motor function.

The US Food and Drug Administration has granted breakthrough designation to MindMed’s lysergide d-tartrate program (MM-120) for the treatment of generalized anxiety disorder.

The original STAR*D authors refute claims of a violated protocol.

H. Steven Moffic, MD, views the Dune book and movies through a psychiatric lens.

Contesters of STAR*D discuss the impact and relevance of the study's remission rates.

"For we are a healing and a growing greenhouse..."

The therapy is the first self-neuromodulation device for PTSD approved by the US Food and Drug Administration.

This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared with intravenous DMT for treatment-resistant depression.

What are your top 3 ethics issues? Take our survey!

STAR*D trial is one of the most important foundational studies in psychiatry to guide the treatment of unipolar major depression. Get ready to explore a dialogue between the original STAR*D authors and a group of authors who call STAR*D into question.